Loading news...
Biotricity (OTCMKTS:BTCY - Get Free Report) and 10x Genomics (NASDAQ: TXG - Get Free Report) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their earnings, risk, institutional ownership, profitability, dividends, analyst recommendations and valuation. Valuation and Earnings This table compares Biotricity and 10x
Biotricity, Inc. (BTCY) Q3 2026 Earnings Call Transcript
REDWOOD CITY, CA, Feb. 11, 2026 (GLOBE NEWSWIRE) -- Biotricity Inc. (OTCQB:BTCY) ("Biotricity" or the "Company”), an innovative Technology-as-a-Service (TaaS) company committed to transforming chronic condition detection and management with state-of-the-art remote patient monitoring solutions, today announced its financial results for its third quarter of fiscal 2026, ended December 31, 2025. Continuing its strong record of scalable revenue, the Company reported sustained revenue growth driven by increasing adoption of its remote cardiac monitoring solutions and improving operating efficiency.
Company continues to drive Revenue Growth, Margin Strength, Operational Efficiency, and continued positive EBITDA REDWOOD CITY, Calif., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Biotricity Inc. (OTCQB:BTCY), an innovative Technology-as-a-Service (TaaS) company committed to redefining the landscape of the healthcare industry with state-of-the-art remote monitoring and diagnostic solutions, announced that it will host its Fiscal 2026 Third Quarter Financial Results and Business Update Call on February 11th, at 4:30 PM Eastern Time.
Biotricity (OTCMKTS:BTCY - Get Free Report) and 111 (NASDAQ: YI - Get Free Report) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their risk, profitability, earnings, dividends, institutional ownership, analyst recommendations and valuation. Analyst Ratings This is a breakdown of recent ratings
Zepp Health (NYSE: ZEPP - Get Free Report) and Biotricity (OTCMKTS:BTCY - Get Free Report) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their valuation, earnings, analyst recommendations, institutional ownership, dividends, profitability and risk. Volatility and Risk Zepp Health has a beta
Three Healthcare IT stocks have surged over 20% in 2025, driven by growth in telehealth, remote monitoring and value-based care platforms.
Biotricity, Inc. (OTC:BTCY) Q2 2026 Earnings Call November 14, 2025 4:30 PM EST Company Participants Waqaas Al-Siddiq - Founder, President, CEO & Chairman S. Ayanoglou - Chief Financial Officer Presentation Operator Good afternoon, and welcome to Biotricity's Second Quarter Fiscal 2026 Financial Results and Business Update Conference Call.
Biotricity Inc. (BTCY) came out with a quarterly loss of $0.03 per share versus the Zacks Consensus Estimate of a loss of $0.08. This compares to a loss of $0.07 per share a year ago.
REDWOOD CITY, CA, Nov. 14, 2025 (GLOBE NEWSWIRE) -- Biotricity Inc. (OTCQB:BTCY) ("Biotricity" or the "Company”), an innovative Technology-as-a-Service (TaaS) company committed to redefining the landscape of the healthcare industry with state-of-the-art remote monitoring and diagnostic solutions, today announced its financial results for its second quarter of fiscal 2026, ended September 30, 2025. Leveraging best-in-class technology, strategic execution, and automation-driven operational efficiencies to maintain margins and expand its footprint, the company is delivering a clear path towards scalable, sustainable growth.
REDWOOD CITY, CA, Nov. 07, 2025 (GLOBE NEWSWIRE) -- Biotricity Inc. (OTCQB:BTCY) ("Biotricity" or the "Company”), an innovative Technology-as-a-Service (TaaS) company committed to redefining the landscape of the healthcare industry with state-of-the-art remote monitoring and diagnostic solutions, announced that it will host its Fiscal 2026 Second Quarter Financial Results and Business Update Call on November 14th, 2025 at 4:30 PM Eastern Time. The Company announces continued strength and progress in financial performance. Biotricity's Founder and CEO, Dr. Waqaas Al-Siddiq, and CFO, John Ayanoglou, will deliver remarks followed by a Q&A section to address questions from investors.
New telehealth offering empowers consumers to use pre-tax healthcare funds at FSA Store® and HSA Store® to make heart health a part of everyday life with at-homemonitoring DALLAS and REDWOOD CITY, Calif. , Sept. 9, 2025 /PRNewswire/ -- Health-E Commerce ®, the parent brand to FSA Store® and HSA Store ®, today announced a new collaboration with Biotricity ® (OTCQB:BTCY), an innovative medical technology company offering clinically reliable solutions for consumers and healthcare professionals.
REDWOOD CITY, Calif./BELFAST, Northern Ireland, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Biotricity Inc. (OTCQB:BTCY), an innovative medical technology company specializing in remote cardiac monitoring solutions, and B-Secur, a leader in ECG algorithm and biosensing technology, are transforming the consumer wearables market with an enhancement to their joint cardiac monitoring platform.
Here is how Biotricity Inc. (BTCY) and Brainsway Ltd. Sponsored ADR (BWAY) have performed compared to their sector so far this year.
Biotricity (BTCY) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
REDWOOD CITY, CA, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Biotricity Inc. (OTCQB:BTCY) ("Biotricity" or the "Company”), an innovative Technology-as-a-Service (TaaS) company committed to redefining the landscape of the healthcare industry with state-of-the-art remote monitoring and diagnostic solutions, today announced its financial results for its first quarter of fiscal 2026, ended June 30, 2025. Dr. Waqaas Al-Siddiq, Biotricity Founder & CEO, said, "We're proud to deliver another quarter of strong performance and a shift to positive EBITDA, which demonstrates the scalability of our business model and strength of our team. Management believes that this a foundational milestone for Biotricity, exemplifying our ability to grow our business as we go from a loss-producing startup to a business that can operate profitably. Following a massive year of positive transformation for Biotricity, we continue to harness the power of workflow automation, AI technology, and other technological enhancements to further improve our operational expenses, margins, and revenues. This powerful combination has set the foundation to fuel ongoing growth. In doing so, we demonstrate our ability to scale with strategic focus and long-term sustainability. The expansion of our Cardiac AI Cloud platform, empowered by strategic partnerships with industry giants, showcases our commitment to revolutionizing medical diagnostics and consumer healthcare. Leveraging over 2 trillion beats of anonymized data, our AI-driven platform is set to enhance clinic profitability, paving the way for transformative advancements in diagnostic accuracy and patient outcomes. Importantly, we remain on track to pursue FDA clearance for our groundbreaking AI clinical model in the coming months.
Company to announce continued Revenue Growth, Improvements in Margins, Operational Efficiency, and a shift to positive EBITDA
The Purpose Bitcoin Yield ETF (BTCY:CA) generates income by writing call options on Bitcoin, sacrificing some upside for current yield. This strategy suits investors seeking income from Bitcoin, but not those focused on maximizing capital appreciation from BTC's price growth. BTCY:CA offers a high distribution yield (around 17.7%), but comes with significant volatility and liquidity concerns, including a wide bid/ask spread.
Biotricity, Inc. (OTC:BTCY) Q4 2025 Earnings Call July 18, 2025 4:45 PM ET Company Participants S. John Ayanoglou - Chief Financial Officer Waqaas Al-Siddiq - Founder, President, CEO & Chairman Conference Call Participants Michael John Donovan - H.C.
REDWOOD CITY, CA, July 17, 2025 (GLOBE NEWSWIRE) -- Biotricity Inc. (OTCQB:BTCY) ("Biotricity" or the "Company"), a Technology-as-a-Service (TaaS) company that offers innovative diagnostic, chronic disease, and lifestyle management solutions for healthcare providers and consumers, today announced its financial results for the fourth quarter and fiscal year ended March 31, 2025.